Summary: In 32 adults with obesity plus prediabetes or newly diagnosed type 2 diabetes, a comparable degree of weight loss achieved by liraglutide or lifestyle counselling was associated with parallel reductions in peripheral mononuclear-cell IL-1β and MASLD extent, with no between-arm difference in IL-1β change (p for difference = 0.56). Baseline IL-1β independently predicted the extent of MASLD improvement (p = 0.030).
PICO Summary
| Element | Detail |
|---|---|
| Population | 32 adults with obesity and impaired glucose metabolism (16 prediabetes, 16 newly diagnosed type 2 diabetes); randomised controlled trial, single-centre, Italy. |
| Intervention | Liraglutide (GLP-1 receptor agonist) titrated until a target weight loss was reached; outcomes assessed at the achieved weight-loss endpoint. |
| Comparison | Lifestyle counselling continued until a comparable degree of weight loss was reached, so the two arms were matched for weight change. |
| Outcome | IL-1β fell comparably in both arms (between-arm p = 0.56), alongside comparable improvements in BMI, glycaemic control, CRP and MASLD extent. Baseline IL-1β independently predicted the extent of MASLD decrease (p = 0.030): the highest IL-1β tertile showed a median MASLD decrease of -8.0 (95% CI -12.3 to -4.8) versus -23.0 (95% CI -39.5 to -16.3) in the lowest tertile. No ARR/NNT applicable (mechanistic/biomarker endpoints). |
Expert Commentary
This small randomised study is best read as a mechanistic and biomarker exploration rather than a therapeutic efficacy trial. By titrating liraglutide and lifestyle counselling to a comparable degree of weight loss, the investigators were able to attribute the parallel falls in mononuclear-cell IL-1β, CRP and MASLD extent to weight reduction itself rather than to a drug-specific effect; the between-arm IL-1β difference was frankly null (p = 0.56), and the design cannot establish that lowering IL-1β causes liver improvement. The more novel signal is predictive: higher baseline IL-1β was associated with a smaller subsequent MASLD decrease, with the lowest tertile improving most. This is an associational, hypothesis-generating finding from 32 participants, and the wide, overlapping confidence intervals demand caution before any clinical inference. The principal limitation is sample size, which leaves the predictive model vulnerable to overfitting and unmeasured confounding, and the open-label design adds further uncertainty. Can I use this with my patients? Not yet; IL-1β is not a validated, standardised, or actionable bedside biomarker, and nothing here changes the existing recommendation that structured weight loss benefits MASLD in this population. The result should prompt adequately powered studies testing whether baseline IL-1β can function as a drug-response biomarker before it enters practice.
References
Simeone PG, Costantino S, Liani R, Tripaldi R, Di Castelnuovo A, Tartaro A, et al. Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):247. doi:10.1186/s12933-025-02706-8